A method for treating allergies and enhancing allergen-specific immunotherapy by administering IL-4R antagonists.

JP2026086598A5Pending Publication Date: 2026-07-21REGENERON PHARMACEUTICALS INC +1

View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office: JP · JP
Patent Type: Applications
Current Assignee / Owner: REGENERON PHARMACEUTICALS INC
Filing Date: 2026-02-06
Publication Date: 2026-07-21

AI Technical Summary

Technical Problem

Current allergen-specific immunotherapy treatments for allergic diseases, such as subcutaneous immunotherapy (SCIT), face challenges with variable efficacy, adverse reactions, and the need for prolonged treatment duration, often requiring years to induce immune tolerance and necessitating frequent medical supervision.

Method used

Administering interleukin-4 receptor (IL-4R) antagonists, such as anti-IL-4R antibodies, before or concurrently with allergen-specific immunotherapy to modulate the immune response, reducing allergen-specific IgE and increasing IgG4, thereby enhancing treatment efficacy, tolerability, and safety.

Benefits of technology

IL-4R antagonists improve the tolerability and safety of SCIT by reducing adverse reactions, shortening treatment duration, and minimizing the need for rescue medications like epinephrine and steroids, while increasing the ratio of allergen-specific IgG4 to IgE, thus enhancing immune tolerance.

✦ Generated by Eureka AI based on patent content.

Patent Text Reader

Abstract

This invention provides a method for enhancing the efficacy, safety, and / or tolerance of grass allergen-specific subcutaneous immunotherapy (SCIT) regimens in subjects with grass allergies. [Solution] A method is provided which includes administering a therapeutic composition containing an interleukin-4 receptor (IL-4R) antagonist, such as an anti-IL-4R antibody or its antigen-binding fragment, to a subject in need.

Need to check novelty before this filing date? Find Prior Art